Table 2.
Tumor and underlying liver histopathology for all patients and stratified by the presence or absence of underlying NASH
| All patients (n=181) | NASH (n=31) | Non-NASH (n=150) | p | |
|---|---|---|---|---|
| Tumor pathology | ||||
| Primary tumor multiplicity | 96 (53.0 %) | 16 (51.6 %) | 80 (53.3 %) | 0.86 |
| Median size of largest tumor (cm) | 6.8 (4.0–9.5) | 7.0 (4.3–10.0) | 6.4 (4.0–9.5) | 0.67 |
| Vascular invasion | ||||
| Macrovascular | 28 (15.5 %) | 11 (35.5 %) | 17 (11.3 %) | 0.01 |
| Microvascular | 27 (14.9 %) | 4 (12.9 %) | 27 (15.3 %) | |
| AJCC 6th edition T stage30 | ||||
| 1 | 85 (47.0 %) | 15 (48.4 %) | 70 (46.7 %) | 0.15 |
| 2 | 45 (24.9 %) | 4 (12.9 %) | 41 (27.3 %) | |
| 3 | 46 (25.4 %) | 12 (38.7 %) | 34 (22.7 %) | |
| 4 | 5 (2.8 %) | 0 | 5 (3.3 %) | |
| Differentiation | ||||
| Well | 18 (9.9 %) | 4 (12.9 %) | 14 (9.3 %) | 0.76 |
| Moderate | 115 (63.5 %) | 20 (64.5 %) | 95 (63.3 %) | |
| Poor | 48 (26.5 %) | 7 (22.6 %) | 41 (27.3 %) | |
| Invasion | ||||
| Vascular | 55 (30.4 %) | 15 (48.4 %) | 40 (26.7 %) | 0.02 |
| Perineural | 20 (11.1 %) | 2 (6.5 %) | 18 (12.0 %) | 0.37 |
| Biliary | 26 (14.4 %) | 7 (22.6 %) | 19 (12.7 %) | 0.15 |
| Resection margin | ||||
| R 0 | 147 (81.2 %) | 25 (80.7 %) | 122 (81.3 %) | 0.93 |
| R 1 | 34 (18.8 %) | 6 (19.4 %) | 28 (18.7 %) | |
| Positive nodal disease | 23 (12.7 %) | 6 (19.4 %) | 17 (11.3 %) | 0.47 |
| Number of lymph nodes examined | 1 (0–3) | 1 (0–4) | 0.5 (0–3) | 0.24 |
| Underlying liver pathology | ||||
| Steatosis | ||||
| Less than 5 % | 79 (43.7 %) | 0 | 79 (52.7 %) | <0.001 |
| 5–33 % | 76 (42.0 %) | 14 (45.2 %) | 62 (41.3 %) | |
| 34–66 % | 14 (7.7 %) | 7 (22.6 %) | 7 (4.7 %) | |
| Greater than 66 % | 12 (6.6 %) | 10 (32.3 %) | 2 (1.3 %) | |
| Lobular inflammation | ||||
| None | 114 (63.0 %) | 8 (25.8 %) | 106 (70.7 %) | <0.001 |
| Spotty (<2 foci/200× field) | 54 (29.8 %) | 15 (48.4 %) | 39 (26.0 %) | |
| Mild (2–4 foci/200× field) | 12 (6.6 %) | 8 (25.8 %) | 4 (2.7 %) | |
| Mod/heavy (>4 foci/200× field) | 1 (0.6 %) | 0 | 1 (0.7 %) | |
| Hepatocyte ballooning | ||||
| None | 156 (86.2 %) | 11 (35.5 %) | 145 (96.7 %) | <0.001 |
| Few | 19 (10.5 %) | 16 (51.6 %) | 3 (2.0 %) | |
| Many | 6 (3.3 %) | 4 (12.9 %) | 2 (1.3 %) | |
| NAFLD activity score [31] | 1 (0–2) | 4 (3–5) | 1 (0–1) | <0.001 |
| NAFLD activity score [31]≥5 | 12 (6.6 %) | 11 (35.5 %) | 1 (0.7 %) | <0.001 |
| Hepatic fibrosis | ||||
| None | 99 (54.7 %) | 6 (19.4 %) | 93 (62.0 %) | <0.001 |
| Perisinusoidal or periportal | 53 (29.3 %) | 13 (41.9 %) | 40 (26.7 %) | |
| Perisinusoidal and periportal | 13 (7.2 %) | 8 (25.8 %) | 5 (3.3 %) | |
| Bridging | 13 (7.2 %) | 3 (9.7 %) | 10 (6.7 %) | |
| Cirrhosis | 3 (1.2 %) | 1 (3.2 %) | 2 (1.3 %) | |
| Portal inflammation | ||||
| None | 87 (48.1 %) | 8 (25.8 %) | 79 (52.7 %) | 0.02 |
| Mild | 73 (40.3 %) | 19 (61.3 %) | 54 (36.0 %) | |
| More than mild | 21 (11.6 %) | 4 (12.9 %) | 17 (11.3 %) | |
| Hepatitis B viral infection | 7 (3.9 %) | 1 (3.2 %) | 6 (4.0 %) | 0.84 |
| Hepatitis C viral infection | 9 (5.0 %) | 2 (6.5 %) | 7 (4.7 %) | 0.67 |
Discrete variable are reported with associated percentages, continuous variables are reported as median (25th–75th percentile)